Study Stopped
Study was not initiated because we could not secure funding.
Smartphone-facilitated Asthma Control
SNAPP
Smartphone-facilitated Medication Notification for Asthma Control in Pediatric Patients (SNAPP) Pilot Study
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The objective of this protocol is to pilot an innovative approach to medication adherence to determine if such an approach will improve inhaled corticosteroid (ICS) medication adherence, a critical gap in improving the health of children with asthma. SNAPP incorporates monitoring, reminders, and dynamic feedback through a smartphone that will improve ICS medication adherence and that the investigators believe will influence the child's future independence and chronic disease-management skills.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Dec 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 28, 2014
CompletedFirst Posted
Study publicly available on registry
July 31, 2014
CompletedStudy Start
First participant enrolled
December 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2025
CompletedNovember 13, 2020
November 1, 2020
3.2 years
July 28, 2014
November 11, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Childhood asthma control test
Measurement of change of C-ACT at 6 months.
6 months
Secondary Outcomes (1)
Fractional excretion of exhaled nitric oxide
6 months
Study Arms (2)
Smartphone Asthma Control
EXPERIMENTALSmartphone Asthma Control
Control
ACTIVE COMPARATORControl group
Interventions
Asthma teaching
Smartphone Asthma Control
Eligibility Criteria
You may qualify if:
- TennCare Medicaid insurance, and an acute exacerbation (45% of our ED patients with acute asthma, section C.11.)
- Parent has a smartphone and wireless account that they agree to use for this study (if randomized to intervention group), anticipated residence in the Nashville Metropolitan Service Area for at least 12 months, willingness to participate in phone-based (wireless or landline) ACT-scoring monthly, and willingness to return at 3, 6 and 12 months for FeNO testing.
- The participant's PCP agrees that patient has moderate or severe persistent asthma and should be on ICS for at least the subsequent 12 months in accordance with NIH-NAEPP expert panel guidelines.87,88
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Vanderbilt University Medical Centerlead
- Aerocrine ABcollaborator
Study Sites (1)
Vanderbilt Children's Hospital
Nashville, Tennessee, 37232, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Donald H Arnold, MD, MPH
Vanderbilt University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Pediatrics and Emergency Medicine
Study Record Dates
First Submitted
July 28, 2014
First Posted
July 31, 2014
Study Start
December 3, 2021
Primary Completion
March 1, 2025
Study Completion
April 1, 2025
Last Updated
November 13, 2020
Record last verified: 2020-11